Weight gain in the treatment with "atypical neuroleptics" - An underestimated side-effect?;Gewichtszunahme bei gabe von atypischen neuroleptika - Eine unterschätzte nebenwirkung?

Fortschritte der Neurologie Psychiatrie

Volumn 68, Issue 12, 2000, Pages 546-556

  Wetterling, T ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE; CLOZAPINE; DOPAMINE 2 RECEPTOR; FLUPHENAZINE; HALOPERIDOL; HISTAMINE H1 RECEPTOR; NEUROLEPTIC AGENT; OLANZAPINE; PHENOTHIAZINE; PIMOZIDE; QUETIAPINE; RISPERIDONE; SEROTONIN 2 RECEPTOR; SULPIRIDE; ZIPRASIDONE; ZOTEPINE;

ARTICLE; DRUG INDUCED DISEASE; HUMAN; LONG TERM CARE; OBESITY; PATIENT COMPLIANCE; RECEPTOR AFFINITY; WEIGHT GAIN;

ANTIPSYCHOTIC AGENTS; HUMANS; WEIGHT GAIN;

EID: 0034502217     PISSN: 07204299     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2000-10037     Document Type: Article

References (113)

1. Utilisation en therapeutique psychiatrique d'une phenothiazine d'action centrale elective (4560 R.P.)
2. Kritische stellungnahme zum begriff der neuroleptika (anhand von pharmakologischen und klinischen Befunden mit Clozapin)
3. Subjektives erleben von patienten mit akuter neuroleptika-induzierter akathisie
4. Mechanisms of action of atypical antipsychotic drugs: A critical analysis
5. Risperidone compared with new and reference antipsychotic drugs: In vitro and in vivo receptor binding
6. What makes an antipsychotic 'atypical'?
7. Introduction: What makes an antipsychotic atypical?
8. Selecting an atypical antipsychotic by combining clinical experience with guidelines from clinical trials
9. Positiv- und negativsymptomatik bei chronisch schizophrenen patienten unter erhaltungstherapie mit flupentixol-decanoat im 12-monats-verlauf
10. Pharmakologische und verhaltenstherapeutische behandlungsstrategien bei persistierender schizophrener negativsymptomatik
11. Antipsychotic-induced weight gain: A comprehensive research synthesis
12. Induction of obesity by psychotropic drugs
13. Weight gain associated with antipsychotic drugs
14. Weight gain associated with neuroleptic medication: A review
15. Weight gain: Side effect of atypical neuroleptics?
16. Novel antipsychotics: Comparison of weight gain liabilities
17. Safety of olanzapine
18. Weight changes during clozapine treatment
19. Risperidone versus perphenazine in the treatment of chronic schizophrenic patients with acute exacerbations
20. Risperidone in the treatment of patients with chronic schizophrenia: A multi-national, multi-centre, double-blind, parallel-group study versus haloperidol
21. The distribution of Body Mass Index among individuals with and without schizophrenia
22. Weight gain among schizophrenic patients treated with clozapine
23. Prevalence of obesity in patients receiving depot antipsychotics
24. Amisulpride in medium-term treatment of dysthymia: A six-month, double-blind safety study versus amitriptyline. AMILONG investigators
25. Amisulpride versus fluoxetine in patients with dysthymia or major depression in partial remission: A double-blind, comparative study
26. Amisulpride versus flupentixol in schizophrenia with predominantly positive symptomatology - A double-blind controlled study comparing a selective D2-1ike antagonist to a mixed D1-/D2-like antagonist
27. Clinical update on amisulpride in deficit schizophrenia
28. Tolerability of remoxipride in the long-term treatment of schizophrenia
29. Double-blind comparative study of remoxipride and thioridazine in the acute phase of schizophrenia
30. Body weight gain after administration of antipsychotic drugs: Correlation with leptin, insulin and reproductive hormones
31. Weight gain induced by clozapine
32. Clozapine et schizophrenies resistantes
33. Differential effect of clozapine on weight: A controlled study
34. Assessment of changes in both weight and frequency of use of medications for the treatment of gastrointestinal symptoms among clozapine-treated patients
35. Clozapine-induced weight gain: Prevalence and clinical relevance
36. Effect of treatment duration on plasma levels of clozapine and N-desmethylclozapine in men and women
37. Clozapine versus typical antipsychotics
38. Clozapine (Leponex) overdosage
39. Olanzapine versus haloperidol: Acute phase results of the international double-blind olanzapine trial
40. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: Results of an international collaborative trial
41. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders
42. Body mass index increase of 58% associated with olanzapine
43. Multiple fixed doses of 'Seroquel' (quetiapine) in patients with acute exacerbation of schizophrenia: A comparison with haloperidol and placebo
44. USS ICI 204,636, an atypical antipsychotic: Efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia
45. A comparison of bd and tid dose regimens of quetiapine (Seroquel) in the treatment of schizophrenia
46. Quetiapine in patients with schizophrenia
47. A comparison of quetiapine (ICI 204,636, 'Seroquel') and haloperidol in schizophrenia
48. A comparison of the effects of quetiapine ('Seroquel') and haloperidol in schizophrenic patients with a history of and a demostrated, partial response to conventional antipsychotic treatment
49. A comparison of quetiapine and chlorpromazine in the treatment of schizophrenia
50. Risperidone versus haloperidol in the treatment of chronic schizophrenic inpatients: A multicentre double-blind comparative study
51. Double-blind comparison of risperidone and haloperidol in schizophrenic and schizoaffective psychoses
52. Randomized, double-blind, controlled trial of risperidone versus clozapine in patients with chronic schizophrenia
53. Risperidone in the treatment of schizophrenia: A meta-analysis of randomized controlled trials
54. The R. Risperidone versus clozapine in treatment-resistant chronic schizophrenia: A randomized double-blind study
55. Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: A 6-week placebo-controlled trial
56. Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: A 4-week placebo-controlled trial
57. A comparison of an atypical and typical antipsychotic, zotepine versus haloperidol in patients with acute exacerbation of schizophrenia: A parallel-group double-blind trial
58. Gewichtszunahme - Eine nebenwirkung von nipolept (Zotepin)?
59. Body weight gain induced by antipsychotic drugs: Mechanisms and management
60. Olanzapine in treatment-resistant bipolar disorder
61. Weight changes with depot neuroleptic maintenance therapy
62. Tolerability and therapeutic effect of clozapine
63. Rapid weight gain, at least in some women, is an expression of a neuroendocrine state characterized by reduced hypothalamic dopaminergic tone
64. Increased body weight associated with prolactin secreting pituitary adenomas: Weight loss with normalization of prolactin levels
65. Serotonin and appetite
66. The role of serotonin in eating disorders
67. Carbohydrate craving in obese people: Suppression by treatments affecting serotoninergic transmission
68. Fluoxetine's effect on weight loss in obese subjects
69. Clinical trial of the effiacy and acceptability of D-fenfluramine in the treatment of neuroleptic-induced obesity
70. Clinical studies with fluoxetine in obesity
71. 2c serotonin receptors
72. Proprietes pharmacodynamiques du chlorhydrate de chloro-3 (dimethylamino-3′propyl) 10 phenothiazine
73. Einzeitige orale glukosebelastung bei langfristig neuroleptisch behandelten schizophrenen
74. Olanzapine increases weight and serum triglyceride levels
75. Novel antipsychotics and new onset diabetes
76. Different influences of classical antipsychotics and clozapine on glucose-insulin homeostasis in patients with schizophrenia or related psychoses
77. Clozapine and associated diabetes mellitus
78. Serum leptin levels increase rapidly after initiation of clozapine therapy
79. Body weight and leptin plasma levels during treatment with antipsychotic drugs
80. Prevalence of smoking among psychiatric outpatients
81. Smoking cessation and weight gain in smokers participating in a behavioral treatment at 3-year follow-up
82. The influence of smoking cessation on the prevalence of overweight in the United States
83. Effects of clozapine on smoking in chronic schizophrenic outpatients
84. Clozapine decreases smoking in patients with chronic schizophrenia
85. Influence of patient related variables on clozapine levels
86. Relationship between clinical efficacy and clozapine concentrations in plasma in schizophrenia: Effect of smoking
87. Clozapine serum concentrations are lower in smoking than in nonsmoking schizophrenic patients
88. Leptin levels in smokers and long-term users of nicotine gum
89. Effects of cigarette smoking and its cessation on body weight and plasma leptin levels
90. Plasma leptin concentrations and lipid profiles during nicotine abstinence
91. The effect of antipsychotic drugs on body weight: A retrospective review
92. Clozapine and weight gain
93. Clinical and economic aspects of risperidone treatment in adults with mental retardation and behavioral disturbance
94. Open-label quetiapine in the treatment of children and adolescents with autistic disorder
95. The efficacy and safety of clozapine versus chlorpromazine in geriatric schizophrenia
96. Current concepts in the pharmacological management of obesity
97. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults - The evidence report
98. Weight, weight change, and coronary heart disease in women: Risk within the "normal" weight range
99. Clinically significant side-effects of lithium treatment. A survey of 237 patients in long-term treatment
100. Weight gain as a predictor of long term clozapine efficiency
101. Differential effect of clozapine on weight: A controlled study
102. Brief psychiatric rating scale (BPRS)
103. Olanzapine: Weight gain and therapeutic efficacy
104. Amisulpride versus risperidone in the treatment of acute schizophrenia
105. Amisulpride vs. risperidone in the treatment of acute exacerbations of schizophrenia
106. Comparative evaluation of conventional and novel antipsychotic drugs with reference to their subjective tolerability, side-effect profile and impact on quality of life
107. The effect of long-term antipsychotic treatment on the body weight of patients suffering from chronic schizophrenia: Clozapine versus classical antipsychotic agents
108. Clozapine in the treatment of 121 out-patients
109. Olanzapine versus placebo: Results of a double-blind, fixed-dose olanzapine trial
110. Olanzapine versus haloperidol in the treatment of schizoaffective disorder
111. Risperidone, a novel antipsychotic, and weight change